Biocon Biologics' Bengaluru Facility Receives VAI Status from US FDA After Insulin Drug Substance Inspection

Biocon Biologics announced that its drug substance facility at Biocon Campus (Site 1) in Bengaluru, Karnataka, has been classified as Voluntary Action Indicated (VAI) by the US Food and Drug Administration (FDA). This classification follows a current Good Manufacturing Practice (cGMP) inspection conducted by the US FDA between February 20-28, 2024, specifically pertaining to the supply of recombinant human insulin (rhI) drug substance to the United States market.​

The VAI classification indicates that while the FDA observed certain conditions requiring attention, no critical violations necessitating immediate regulatory or administrative action were identified. In regulatory terms, VAI is generally viewed as an acceptable outcome, reflecting compliance with US quality standards without mandating corrective measures before product approval or market continuation.​

Biocon Biologics reaffirmed its commitment to maintaining global standards of quality and compliance across all its manufacturing operations.​

Key Highlights:

Facility: Drug Substance facility at Biocon Campus (Site 1), Bengaluru, Karnataka.

Classification: Voluntary Action Indicated (VAI) status granted by US FDA.

Inspection period: February 20-28, 2024, focused on cGMP compliance.

Product scope: Supply of recombinant human insulin (rhI) drug substance to the US market.

Regulatory implication: VAI indicates objectionable conditions found but no immediate regulatory action required.

Company commitment: Biocon Biologics remains dedicated to global quality and compliance standards.

Sources: Economic Times, Biocon official press release, NSE India filing, Pharmabiz, Business Upturn.​